Previous work have shown that blood cells share 84% of their transcriptome with the heart and that some gene regulations in blood are similar to other organs such as the heart. Thus, peripheral blood is likely to become a useful resource in the diagnosis of systemic diseases,ASMI selection of treatment methods and disease outcome prediction. In this work we show that white blood cells retain information of ALVD and provide a set of genes that could be used to pre-screen patients for ALVD before time-consuming echocardiographic confirmation of the disease. Recent randomized clinical trials and a major meta-analysis have emphasized the importance of LDL-cholesterol lowering for cardiovascular risk reduction in diabetes mellitus. Therefore the current treatment guidelines advocate aggressive multifactorial risk factor intervention in patients with diabetes. The European guidelines promote lifestyle changes and lipid lowering therapy in order to reach a lower LDL-C value than 2.5 mmol/L, or 1.8 mmol/L or lower if overt cardiovascular disease is present. The pharmacological treatment should be based on HMG CoA reductase inhibitors, also known as statins, but other options are to be considered if the treatment goals are not reached. The LDL-C lowering effects of the different statins in clinical trials have recently been reviewed. A small or moderate dose of statins could decrease LDL-C by AS8351 with small differences between the different agents. These conclusions are in agreement with the CURVES and the STELLAR studies, in which atorvastatin and rosuvastatin, respectively, showed similar effects as other statin. At higher doses, however, atorvastatin and rosuvastatin are the only agents that can lower LDL-C more than 40%. There have not been any randomized clinical trials or observational epidemiological studies with head to head comparisons of the cholesterol lowering effect by different statins in patients with diabetes. The aim of this observational study linking data from the Swedish National Diabetes Register, a quality register with nation-wide coverage, with two other national population-based registers, was to describe the use and evaluate the LDL-C lowering effects of different lipid lowering therapies in 37 182 unselected patients with type 1 and type 2 diabetes in clinical practice.